Serzone Pulled from U.S. Market

Bristol-Myers Squibb announced today that it is pulling its antidepressant Serzone (nefazodone) from the U.S. market. The controversial antidepressant has already been banned from sale in many countries because of links to cases of liver failure and injury, and at least 20 deaths. Some are arguing that the FDA should still ban the medication, since it will remain available as a generic.
Read more: Serzone Pulled from U.S. Market